hVIVO plc (AIM:HVO)
London
· Delayed Price · Currency is GBP · Price in GBX | Market Cap | 50.50M |
| Revenue (ttm) | 49.66M |
| Net Income (ttm) | -5.99M |
| Shares Out | 687.01M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 0.00 (0.03%) |
| Ex-Dividend Date | May 15, 2025 |
| Volume | 4,757,979 |
| Average Volume | 4,814,368 |
| Open | 7.30 |
| Previous Close | 7.35 |
| Day's Range | 7.02 - 7.50 |
| 52-Week Range | 4.31 - 19.50 |
| Beta | 1.67 |
| RSI | 43.51 |
| Earnings Date | Apr 15, 2026 |
About hVIVO
hVIVO plc operates as a pharmaceutical service and contract research company in the United Kingdom, Europe, and North America. The company is involved in the testing of vaccines and antivirals using human challenge clinical trials; and provision of laboratory services, including assay development, cell based assays, molecular, immunology, virology, clinical field trail logistics, and biomarker analysis services. It has a portfolio of human challenge study models for conditions, such as RSV, influenza, COVID-19, hMPV, HRV, asthma, malaria, and C... [Read more]
Financial Performance
Financial StatementsNews
Full Year 2025 hVIVO PLC Earnings Presentation Transcript
Full Year 2025 hVIVO PLC Earnings Presentation Transcript
hVIVO Earnings Call Transcript: H2 2025
2025 saw financial challenges from trial cancellations, but operational progress included acquisitions, rebranding, and diversification into new clinical and geographic areas. Human challenge trials remain core, but non-challenge revenue now exceeds 50%, supporting a strong outlook for 2026.
hVIVO Earnings Call Transcript: Q4 2025
FY25 revenue met guidance at GBP 46.7m, with positive EBITDA margin and strong cash position. Acquisitions expanded services and geographic reach, while diversification reduced reliance on HCT. Guidance for 2026 is high single-digit growth, supported by a robust pipeline.
Full Year 2024 hVIVO PLC Investor Presentation Transcript
Full Year 2024 hVIVO PLC Investor Presentation Transcript
Half Year 2025 hVIVO PLC Earnings Presentation Transcript
Half Year 2025 hVIVO PLC Earnings Presentation Transcript
hVIVO Earnings Call Transcript: H1 2025
Revenue for H1 2025 declined year-over-year, but acquisitions and diversification into new service lines partially offset the impact of headwinds in human challenge clinical trials. Cash remains strong, and guidance for 2025 is reiterated, with growth and profitability expected in 2026–2027.
hVIVO Earnings Call Transcript: H1 2025
H1 2025 saw £24.2m revenue and 12% EBITDA margin, with strong cash reserves and ongoing integration of CRS and Cryostore. Despite market headwinds and project cancellations, a robust sales pipeline and improved operational efficiencies support a positive outlook for 2025 and beyond.
hVIVO Earnings Call Transcript: H2 2024
Record revenue and EBITDA growth achieved, with strong cash reserves and expanded service offerings through acquisitions. Guidance for 2025 remains robust, despite macro headwinds and a temporary margin dip due to integration costs. Regulatory milestones and a diversified pipeline support long-term growth.
Cathal Friel to step down as HVivo chairman
Cathal Friel, the co-founder of pharmaceutical services firm HVivo, formerly Open Orphan, is to step down as chairman of the group.
hVIVO Transcript: M&A Announcement
The acquisition of two German clinical research units expands service offerings, client base, and geographic reach, supporting the goal of becoming a leading early-stage clinical development provider in Europe. Integration is expected to deliver operational synergies and margin improvements, with CRS targeted to become earnings accretive by 2026.
ILiAD and hVIVO Sign LOI for Pivotal Phase 3 Trial of BPZE1 Pertussis Vaccine Following FDA Meeting
WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, LLC, a biotech company developing BPZE1, the most advanced next generation intranasal pertussis vaccine to protect against whooping cough, today a...
Half Year 2024 hVIVO PLC Investor Presentation Transcript
Half Year 2024 hVIVO PLC Investor Presentation Transcript
Earnings rise 68pc at pharmaceutical services firm Hvivo
Pharmaceutical services firm Hvivo, formerly Open Orphan, has recorded a 67.6pc jump in earnings in the first six months of the year.
hVIVO Earnings Call Transcript: H1 2024
Record H1 2024 revenue and EBITDA growth were driven by strong demand for human challenge trials, operational efficiencies, and expanded service offerings. The new Canary Wharf facility increased capacity and enabled new revenue streams, supporting a robust outlook and ambitious 2028 targets.
hVIVO Transcript: CMD 2024
Revenue grew 31% year-on-year to GBP 35.6 million in H1 2024, driven by expanded capacity and operational efficiencies from a new Canary Wharf facility. Strategic focus includes broadening service offerings, targeting GBP 100 million revenue by 2028, and leveraging a robust sales pipeline and advanced recruitment platform.